The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that underscores the growing integration of semiconductor technology in healthcare, Butterfly Network has partnered with Midjourney Medical to develop a novel full-body scanner. The prototype scanner incorporates 40 of Butterfly's proprietary Ultrasound-on-Chip imaging modules, marking a significant application of its semiconductor-based technology. This collaboration is part of a co-development agreement where Midjourney licenses Butterfly’s hardware for its next-generation tomographic imaging machines.
Sign in to access this content
Sign InThis partnership serves as a validation of Butterfly's chip technology in third-party hardware, positioning it against industry incumbents like GE HealthCare. Per market data, the shift toward silicon-based ultrasound solutions offers potential cost reductions and portability advantages over traditional piezoelectric systems. Recent industry trends highlight an increasing reliance on AI-driven diagnostic tools, a sector where Butterfly's digital platform seeks to capture a larger market share.
Regarding market performance, BFLY shares stood at $5.71 (at close June 17, 2026), having reached a high of $6.14 during the session. Investors are looking for signs of commercial scale-up and licensing revenue growth from this collaboration. Looking ahead, broader market sentiment remains influenced by recent data such as the Michigan Consumer Sentiment index, which reported a reading of 48.9 on June 12, 2026, reflecting the cautious macroeconomic backdrop for growth-stage healthtech firms.